Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.56 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.56 |
| ▸ | PIK3CD | O00329 | 12/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.51 |
| ▸ | MTOR | P42345 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1088049 | 0.95 | PIK3CA (0.58) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1087347 | 0.91 | PIK3CD (0.53) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181174 | 0.91 | PIK3CD (0.53) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181064 | 0.91 | PIK3CA (0.57) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL189736 | 0.90 | PIK3CA (0.53) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL190232 | 0.90 | PIK3CA (0.63) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13640296 | 0.90 | PIK3CA (0.59) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181139 | 0.89 | PIK3CD (0.53) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL994059 | 0.89 | PIK3CA (0.55) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| Hydrochloric Acid SCHEMBL1182606 | 0.89 | PIK3CA (0.53) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4412617-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2023058003-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC (US) | 2023-04-13 | — | — | WO | disclosed |
| US-9725461-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8906909-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8697693-B2 | Pharmaceutical compounds | F. Hoffmann LaRoche AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-8461157-B2 | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | CURIS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-11-08 | — | — | US | disclosed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-8252792-B2 | Pyrimidine derivatives as PI3K inhibitors | F. HOFFMAN-LA ROCHE AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | CURIS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-21 | — | — | US | disclosed |
| WO-2007122410-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155595-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885PIK3CD 37/4885 |
| US-20120283257-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3R5 | PIK3CA 1/4885PIK3R1 4/4885PIK3CD 2/4885 |
| US-20120088764-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885PIK3CD 37/4885 |
| US-20100016306-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 4/4885PIK3CD 2/4885 |
| US-20150203509-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITORS WITH A ZINC BINDING MOIETY | BAZ2A, BAZ2B, PI4KB | PIK3CA 58/4885PIK3R1 106/4885PIK3CD 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.